Yaupon Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Yaupon Therapeutics's estimated annual revenue is currently $1.7M per year.
- Yaupon Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Yaupon Therapeutics has 11 Employees.
- Yaupon Therapeutics grew their employee count by 0% last year.
Yaupon Therapeutics's People
Name | Title | Email/Phone |
---|
Yaupon Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Yaupon Therapeutics?
Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.
keywords:N/AN/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 11 | -8% | N/A |
#2 | $2.5M | 16 | 23% | N/A |
#3 | $1.6M | 22 | -31% | $17.2M |
#4 | $2M | 22 | 10% | N/A |
#5 | $2.5M | 24 | -20% | $4M |